Post job

Explore jobs

Find specific jobs

Explore careers

Explore professions

Best companies

Explore companies

Attralus CEO and leadership

Zippia score 3.6
OverviewRevenue

Reviews

CEO & Executives

Attralus CEO and executives

Executive Summary. Based on our data team's research, Mark Timney is the Attralus's CEO. Attralus has 30 employees, of which 2 are in a leadership position.
Work at Attralus?
Share your experience

Rate Attralus' leaders' effectiveness in guiding the company.

Zippia waving zebra
Name & TitleBio
Mark Timney

CEO

Mark Timney's LinkedIn

Jonathan Wall

Co-Founder & Interim Chief Scientific Officer

Jonathan Wall is a Professor at University of Tennessee Medical Center, Knoxville and Head of the Amyloidosis and Cancer Theranostics Program. Jonathan is an internationally known expert in the field of amyloidosis and has worked in the field of amyloidosis for over 25 years.

He has over 100 publications and more than 13 issued US patents in this field. His research work was instrumental in the development of multiple antibody-based therapeutics that have undergone clinical development by biotech companies. His lab has received over $10M in NIH grant and contract funding for work that focuses on the development and translation of novel diagnostic and therapeutic reagents for amyloidosis.

Do you work at Attralus?

Does leadership effectively guide Attralus toward its goals?

Attralus jobs

Attralus founders

Name & TitleBio
Jonathan Wall

Co-Founder & Interim Chief Scientific Officer

Jonathan Wall is a Professor at University of Tennessee Medical Center, Knoxville and Head of the Amyloidosis and Cancer Theranostics Program. Jonathan is an internationally known expert in the field of amyloidosis and has worked in the field of amyloidosis for over 25 years.

He has over 100 publications and more than 13 issued US patents in this field. His research work was instrumental in the development of multiple antibody-based therapeutics that have undergone clinical development by biotech companies. His lab has received over $10M in NIH grant and contract funding for work that focuses on the development and translation of novel diagnostic and therapeutic reagents for amyloidosis.

Attralus executives FAQs

Most in demand jobs

Updated November 18, 2022

Zippia gives an in-depth look into the details of Attralus, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Attralus. The employee data is based on information from people who have self-reported their past or current employments at Attralus. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Attralus. The data presented on this page does not represent the view of Attralus and its employees or that of Zippia.

Attralus may also be known as or be related to Attralus and Attralus, Inc.